Resources » Learning Center » Protein & Antibody Academy » Explore 30 most popular BsAb Formats in GenScript's Antibody Design Tool: Structures, Features & FDA-Approved Drug List

Explore 30 most popular BsAb Formats in GenScript's Antibody Design Tool: Structures, Features & FDA-Approved Drug List

Dec 19, 2025

Keywords

Duration: 6 min

Jeffery Shi

Protein and Antibody Product Marketing

Jeffrey Shi, Head of Protein and Antibody Product Marketing Team of Marketing Department. He and his team are responsible for customer-centric development of full product life cycle management for Protein and Antibody, and drive the sustainable development of the protein antibody business.

Talk to Author

CONTENTS

Asymmetric Bi-specific Antibody

Format Format Description FDA-Approved Antibody Drug in this format Details
1 CrossMab(CH1-CL) CrossMab(CH1-CL)
  • Using KIH strategy to suppress heavy chain mispairing
  • Swapping the Fab's CH1 and CL to suppress light chain mispairing
  • Vanucizumab, RO5520985 (Roche)
  • RO7121661, RG7769 (Roche)– Clinical Phase II
  • Faricimab, RO6867461, RG7716 (Roche)
  • 10E8.4/iMab，TMB-370 (ADARC)
View
2 Fab/scFv-Fc Fab/scFv-Fc
  • Using KIH strategy to suppress heavy chain mispairing
  • scFv fragment: To prevent mispairing of light chains, VH2 is connected to the corresponding VL2 through a linker and the scFv fragment is connected to a heavy chain
  • Vibecotamab, Xmab14045 (Xencor)
  • Plamotamab, XmAb13676 (Xencor)
  • M802 (YZYBio)
  • Tidutamab, XmAb18087 (Xencor)
  • XmAb20717 (Xencor) – Clinical Phase II
  • ZW25 (Zymeworks)
  • ZW49 (Zymeworks)
  • M701 (YZYBio)
View
3 Heterodimeric IgG(Common LC) Heterodimeric IgG(Common LC)
  • Using Biclonics, ART-Ig or CRIB strategies to suppress heavy chain mispairing
  • The light chain obtained through screening can bind to two types of antibody heavy chains to prevent light chain mispairing.
  • Plamotamab, XmAb13676 (Xencor) – Clinical Phase I
  • ERY974 (Chugai)
  • REGN4018 (Regeneron) – Clinical Phase I/II
  • MCLA-145 (Merus, Incyte)
  • Zenocutuzumab, MCLA-128, PB4188 (Merus)
  • MCLA-158 (Merus) – Clinical Phase I/II
  • Navicixizumab, OMP-305B83 (Celgene/Oncomed) – Clinical Phase II
  • KN046 (Alphamab) – Clinical Phase II
  • KN026 (Alphamab) – Clinical Phase II
  • Emicizumab, Hemlibra, ACE910, RO5534262 (Chugai, Roche)
View
4 Heterodimeric scFv-Fc Heterodimeric scFv-Fc
  • Using KIH strategy to suppress heavy chain mispairing
  • To prevent mispairing of light chains, VH1/VH2 is connected to the corresponding VL1/VL2 through a linker and then each scFv fragment is connected to a heavy chain respectively
N/A View
5 CrossMab(VH-VL) CrossMab(VH-VL)
  • Using KIH strategy to suppress heavy chain mispairing
  • Swapping the Fab's VH and VL to suppress light chain mispairing
N/A View
6 Duobody Duobody
  • Epcoritamab-bysp (EPCORE™) (Genmab + AbbVie)
 View
7 Heterodimeric-IgG(in vitro assembly) Heterodimeric-IgG(in vitro assembly) N/A View
8 Fab/VHH-Fc Fab/VHH-Fc N/A View
9 CrossMab(Fab) CrossMab(Fab)
  • Faricimab-svoa, RO6867461, RG7716 (Roche / Genentech)
  • Mosunetuzumab (RG7827, RO7144795) – Roche / Genentech
View
10 Fab-IgG(CrossMab(VH-VL)) Fab-IgG(CrossMab(VH-VL)) N/A View
11 Mono BiTE-Fc Mono BiTE-Fc N/A View
12 Fab-scFv/Fab-Fc (common LC) Fab-scFv/Fab-Fc (common LC) N/A View

Symmetric Bi-specific Antibody

Format Format Description FDA-Approved Antibody Drug in this format Details
13 scFv-IgG(LC) scFv-IgG(LC) N/A View
14 scFv-IgG (HC) scFv-IgG (HC)
  • Symmetric Bi-specific Antibody avoids the problem of light chain and heavy chain mispairing
  • This format links the scFv to the N-terminus of the heavy chain of a normal IgG antibody molecule.
N/A View
15 IgG-scFv (HC) IgG-scFv (HC)
  • Symmetric Bi-specific Antibody avoids the problem of light chain and heavy chain mispairing
  • This format links the scFv to the C-terminus of the heavy chain of a normal IgG antibody molecule.
  • NOV1501, ABL001, TR009 (ABL Bio)
  • Tibulizumab, LY3090106 – Clinical Phase I
 View
16 IgG-scFv (LC) IgG-scFv (LC)
  • Symmetric Bi-specific Antibody avoids the problem of light chain and heavy chain mispairing
  • This format links the scFv to the C-terminus of the light chain of a normal IgG antibody molecule.
N/A View
17 IgG-VHH(HC) IgG-VHH(HC) N/A View
18 Multiple-VHH-Fc Multiple-VHH-Fc N/A View
19 VHH-IgG(HC) VHH-IgG(HC) N/A View
20 DVD-Ig DVD-Ig N/A View
21 BiTE-Fc BiTE-Fc
  • AMG 757 (Amgen, DLL3 × CD3)
  • Linvoseltamab, REGN5458 (Regeneron, BCMA × CD3)
 View
22 Fab-VHH(HC)-Fc Fab-VHH(HC)-Fc N/A View
23 IgG-VHH2(HC) IgG-VHH2(HC) N/A View
24 BiTE-scFc BiTE-scFc N/A View

Bi-specific Antibody Fragments

Format Format Description FDA-Approved Antibody Drug in this format Details
25 scFv-Fab scFv-Fab
  • Bi-specific Antibody Fragments avoids chain mispairing
  • Connect an scFv molecule to the N-terminus of VH in Fab.
  • A-319 (Generon) – Clinical Phase I
 View
26 Fab-scFv Fab-scFv
  • Bi-specific Antibody Fragments avoids chain mispairing
  • Connect an scFv molecule to the C-terminus of CH1 in Fab
N/A View
27 BiT BiTE
  • Bi-specific Antibody Fragments avoids chain mispairing
  • Connect the anti-CD3 scFv with the anti-tumor cell scFv through a linker
  • Blinatumomab, Blincyto, MT103, MEDI-538, AMG103 (Amgen)
  • RG6160, RO7187797, BFCR4350A (Genentech) – Clinical Phase I
  • Pasotuxizumab A212, BAY2010112– Clinical Phase I
View
28 Multiple-VHH Multiple-VHH N/A View
29 scDb(sc-Diabody) scDb(sc-Diabody) N/A View
30 Fab-VHH Fab-VHH N/A View

Note： The sequence we referenced comes from Uniprot.

1. The source of hIgG4 sequence: IGHG4 - Immunoglobulin heavy constant gamma 4 - Homo sapiens (Human) | UniProtKB | UniProt

2. The source of CLκ sequence: IGKC - Immunoglobulin kappa constant - Homo sapiens (Human) | UniProtKB | UniProt

3. The source of CLλ sequence: IGLC2 - Immunoglobulin lambda constant 2 - Homo sapiens (Human) | UniProtKB | UniProt

Genscript Antibody Design Tool

Receive GenScript's
Latest Insight Sharing

* We'll never share your email address with a third-party.

Related Articles

CrossMab Technology: Precise Light and Heavy Chain Pairing for Bispecific Antibodies

CrossMab technology, developed by Roche in 0211, enables efficient production of bispecific antibodies by ensuring correct pairing of light and heavy chains through domain exchange and Knob-Into-Hole heterodimerization,

May 12, 2025

Comprehensive Guide to Bispecific Antibodies: Formats, Recombinant Antibody Production, and Emerging Trends

Bispecific antibodies (bsAbs) have made significant strides in precision medicine, with 11 products approved by the FDA by December 2023, and ongoing research aims to overcome challenges and unlock their full therapeutic potential.

Feb 19, 2025

Comprehensive Guide to Bispecific Antibodies: Recent Advances in Mechanisms, Advantages, and Applications

Bispecific antibodies (BsAbs) are a medical breakthrough that target two antigens simultaneously, enhancing treatment specificity and efficacy while reducing off-target effects. This dual-targeting shows promise in treating complex diseases like cancer an

Feb 12, 2025

Previous Article

Mar 28, 2025

AI as a Molecular Tailor: Redesigning Antibodies for the Humanization

Next Article

Apr 21, 2025

Lentivirus: The Ultimate Answer for Efficient Gene Delivery